Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification
June 24, 2024 08:00 ET
|
Panbela Therapeutics, Inc.
DSMB Recommends Continuation without Modification for Third TimeSafety Review Included 395 PatientsInterim Survival Analysis Still Expected Early 2025 given Lower-Than-Expected Event Rate Low...
Panbela Announces Oral Presentation at Digestive Disease Week (DDW):
June 10, 2024 08:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, June 10, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Provides Business Update and Reports Q1 2024 Financial Results
May 15, 2024 16:10 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, May 15, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...
Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac
May 06, 2024 08:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, May 06, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024
May 01, 2024 16:15 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, May 01, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Acceptance of Eflornithine (DFMO) Abstract for Oral Presentation at Digestive Disease Week
April 30, 2024 08:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 30, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients...
Panbela Therapeutics Announces Interim Data Analysis for ASPIRE Trial Pushed to Q1 2025
April 22, 2024 08:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 22, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Announces Poster Presentation at American Association for Cancer Research:
April 18, 2024 08:00 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 18, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA)(“Panbela”), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment...
Panbela Announces Transfer to OTCQB Market
April 16, 2024 17:29 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, April 16, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (OTCQB: PBLA), (“Panbela”), a clinical stage company developing disruptive therapeutics for the treatment of patients with...
Panbela Provides Business Update and Reports Q4 and FY 2024 Financial Results
March 26, 2024 16:10 ET
|
Panbela Therapeutics, Inc.
MINNEAPOLIS, March 26, 2024 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (NASDAQ:PBLA), a clinical stage company developing disruptive therapeutics for the treatment of patients with urgent unmet...